Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

UK Pharma R&D


Published on

R&D in UK's Pharma Companies.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

UK Pharma R&D

  1. 1. R&D in UKsPharmaceuticalCompaniesGroup #3:Ahmed Abuiliazeed Diaa el BagouryOsama Hagag Mohamed Tarek
  2. 2. Presentation Structure:1. Overview.2. UK Pharma Now and Then.3. Problem Definition.4. Research Methodology.5. Challenges and Solutions
  3. 3. Overview● Competition with global market fueled theneed for more R&D activities and innovation.● R&D staff size, and R&D expenditures leadto more innovation in the company?● Level of innovation compared to the relativesize of the corporation.● Data sources:○ Loss of easy access to data due to large companymergers.○ Power of public data records
  4. 4. UK Pharma Industry Now:● Economic value of the industry
  5. 5. UK Pharma Industry Now:● R&D expenditures by sector
  6. 6. History● Number of new chemical entities per year
  7. 7. History● Local vs Global Market
  8. 8. Problem Definition● UK falling behind competitors in thepharmaceutical industry○ Emerging economies○ Developed economies○ Lack of government investment● Solutions:○ Change business model○ Actions against counterfeit medicine○ Understanding global competition○ Preventive medicine through focus on R&D
  9. 9. Problem Definition● Companies with more focus on R&D moresuccessful?● Relation between innovation - company size.● How to quantify innovation?○ Papers○ Patents○ New drugs.● Company size measured through R&D○ R&D expenditure○ Number of researchers.
  10. 10. Research Methodology● The hypothesis of the research was basedon finding relationship between research andinnovation.● Claire decided to consider R&D expenditure,Number of scientists employed as researchindicators.● She also considered number of patents,research papers and new drugs produced asindicators for new innovations.
  11. 11. Data Resources & Classification1. Number of patents taken out of the company.2. Number of scientific papers published by its scientists.3. Number of drugs theyve launched on the marketbetween 1960 and 1969.4. Companies R&D expenditure.5. Number of scientists employed in R&D departments.
  12. 12. Data Resources & ClassificationThe data was collected from:● 6 pharmaceutical companies● Publications by the Department of trade, Department ofHealth.● Patent office● National Economic Development Office.● Reports from stockbrokers● Association of British Pharmaceutical Industry (ABPI).● Publications and good quality journalist Reports on theIndustry.
  13. 13. Additional Resources● Interviews with the R&D departments headsof the top 10 Pharmaceutical companies inUK.● survey with 1000 participants from thepharmaceutical industry.
  14. 14. Research Challenges& Solutions● Company merges moved archives around.● Difficult to get data from companies.● Some of the public data available was undera 30-year closure rule.● Public data sometimes not comprehensiveenough.Solution:● Extract information from ministry of healthcommittees.● Wait until data becomes available eventually
  15. 15. Lessons Learned● Keep an eye on the availability of data onthe subject, to not waste time or draw falseconclusions.● Raw data from the primary sources would bemost accurate.
  16. 16. References :1. Research and development in the UK pharmaceutical industry in the1960s.2. The UK Pharmaceutical Industry: Current Challenges and FutureSolutions3. Employment in the pharmaceutical industry in the UK4. Pharmaceutical innovation by the seven UK-owned pharmaceuticalcompanies (1964-1985)
  17. 17. Thanks